<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Nivolumab induced discolouration of the tongue: a case report

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Yildirim, Dilek

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Currently, immune checkpoint inhibitors are used in the treatment of ovarian cancer. Immunotherapy agents occasionally cause the development of skin reactions characterized by mild erythematous and maculopapular rashes, usually involving the trunk and extremities of the body, which may occasionally present with pruritus. It is especially seen in the use of anti-PD-1 (nivolumab and pembrolizumab) treatment agents. In this case report, we present a patient who developed discoloration of the tongue toxicity after nivolumab treatment in ovarian cancer patients. Discoloration of the tongue, which is one of the rare side effects of immunotherapy, and factors that may be associated with it are discussed in this case.

Source

Publisher

Taylor and Francis

Citation

item.page.haspartof

Source

Immunotherapy

item.page.ispartofseries

item.page.edition

DOI

10.1080/1750743X.2025.2533105

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators